AI
Thursday, June 17, 2021 10:22:48 PM
https://www.drugpatentwatch.com/p/tradename/VYVANSE
Drug patent watch said that by analyzing the patents and regulatory protections for Vyvance, it appears that the earliest date for generic entry will be February 24, 2023. This may change due to patent challenges or generic licensing.
What is interesting about that is it would allow Elite to target Vyvance as one of their four generic submissions in 2023 and here is why that might be a very good thing…
Recent ELTP News
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
